{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T18:20:11Z","timestamp":1775931611429,"version":"3.50.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1097\/jcp.0b013e31824997a8","type":"journal-article","created":{"date-parts":[[2012,3,4]],"date-time":"2012-03-04T05:02:23Z","timestamp":1330837343000},"page":"287-289","source":"Crossref","is-referenced-by-count":13,"title":["Interindividual Variation in Olanzapine Concentration Influenced by UGT1A4 L48V Polymorphism in Serum and Upstream FMO Polymorphisms in Cerebrospinal Fluid"],"prefix":"10.1097","volume":"32","author":[{"given":"Mao","family":"Mao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Skogh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Gabriella","family":"Scordo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marja-Liisa","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-23-20210128","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00213-003-1529-4","article-title":"Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses.","volume":"170","author":"Melkersson","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"R2-23-20210128","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/01.jcp.0000162800.64378.82","article-title":". The association of weight gain and olanzapine plasma concentrations.","volume":"25","author":"Perry","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"R3-23-20210128","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/JCP.0b013e318204d9e2","article-title":". High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug.","volume":"31","author":"Skogh","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"R4-23-20210128","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00004714-200304000-00003","article-title":". Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine.","volume":"23","author":"Carrillo","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"R5-23-20210128","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00228-009-0783-8","article-title":". Carriers of the UGT1A4 142TG gene variant are predisposed to reduced olanzapine exposurean impact similar to male gender or smoking in schizophrenic patients.","volume":"66","author":"Ghotbi","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"R6-23-20210128","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/tpj.2009.32","article-title":". Pharmacogenetics and olanzapine treatment: CYP1A21F and serotonergic polymorphisms influence therapeutic outcome.","volume":"10","author":"Laika","year":"2010","journal-title":"Pharmacogenomics J"},{"key":"R7-23-20210128","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/FTD.0b013e31816336fd","article-title":". The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP).","volume":"30","author":"Nozawa","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R8-23-20210128","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hup.403","article-title":"Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes.","volume":"17","author":"Linnet","year":"2002","journal-title":"Hum Psychopharmacol"},{"key":"R9-23-20210128","first-page":"658","article-title":". Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine.","volume":"276","author":"Ring","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"R10-23-20210128","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.taap.2008.02.020","article-title":". Genetic variability of aryl hydrocarbon receptor (AhR)-mediated regulation of the human UDP glucuronosyltransferase (UGT) 1A4 gene.","volume":"230","author":"Erichsen","year":"2008","journal-title":"Toxicol Appl Pharmacol"},{"key":"R11-23-20210128","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.pharmthera.2005.01.001","article-title":"Mammalian flavin-containing monooxygenases: structurefunction, genetic polymorphisms and role in drug metabolism.","volume":"106","author":"Krueger","year":"2005","journal-title":"Pharmacol Ther"},{"key":"R12-23-20210128","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1124\/jpet.103.053686","article-title":". Genetic variability at the human FMO1 locus: significance of a basal promoter yin yang 1 element polymorphism (FMO16).","volume":"306","author":"Hines","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R13-23-20210128","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1124\/mol.105.012062","article-title":". Discovery of novel flavin-containing monooxygenase 3 (FMO3) single nucleotide polymorphisms and functional analysis of upstream haplotype variants.","volume":"68","author":"Koukouritaki","year":"2005","journal-title":"Mol Pharmacol"},{"key":"R14-23-20210128","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1006\/abbi.1999.1155","article-title":". Expression of UDP-glucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and identification of 5-hydroxytryptamine as a substrate.","volume":"365","author":"King","year":"1999","journal-title":"Arch Biochem Biophys"},{"key":"R15-23-20210128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1124\/dmd.105.006171","article-title":"Quantitative analysis of FMO gene mRNA levels in human tissues.","volume":"34","author":"Zhang","year":"2006","journal-title":"Drug Metab Dispos"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004714-201204000-00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:17:44Z","timestamp":1618035464000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201204000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31824997a8","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}